BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
Richard D. Press(Oregon Health & Science University), Brian Druker(Oregon Health & Science University), Solange Mongoue‐Tchokote(Howard Hughes Medical Institute), Rui Yang(Tianjin University of Science and Technology), Michael J. Mauro(Memorial Sloan Kettering Cancer Center), Thuan V. Tran(Howard Hughes Medical Institute), Zac Love(Howard Hughes Medical Institute), Ashlie Tronnes(Howard Hughes Medical Institute), Motomi Mori(St. Jude Children's Research Hospital), Michael W. Deininger(Versiti Blood Center of Wisconsin)
Cited by 126
Related Papers
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464